Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: RISPERDAL
Published 2025-12-21 · Last reviewed 2025-12-28 · 5 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Risperidone (brand Risperdal and numerous generics) is a second-generation antipsychotic available in oral, orally disintegrating, solution, and long-acting injectable forms for schizophrenia, bipolar disorder, and irritability in autism.
This profile highlights schizophrenia, bipolar I mania/mixed episodes, and long-acting injectable maintenance where predictable dosing and depot options are valuable.
Risperidone mechanism of action centres on serotonin-dopamine antagonism with active metabolite paliperidone, enabling once-daily and long-acting strategies when cross-titrated thoughtfully.
The compare view and the Risperidone evidence feed can help balance prolactin, metabolic, and LAI considerations alongside the bipolar disorder hub when planning mood disorder regimens.
Widely used due to efficacy and depot options, though clinicians monitor prolactin elevation, EPS, and weight gain. Often chosen for predictable oral-to-LAI conversions.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Risperidone antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, balancing psychosis control with mitigation of EPS compared to typical antipsychotics.
Additional antagonism at adrenergic α1/α2 and histamine H1 receptors contributes to hypotension and sedation, while minimal muscarinic activity limits anticholinergic effects.